Advaxis (NASDAQ:ADXS) posted its quarterly earnings results on Monday. The biotechnology company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.06, Yahoo Finance reports. Advaxis had a negative net margin of 940.64% and a negative return on equity of 131.78%. The company had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.03 million.
Shares of Advaxis (ADXS) opened at $1.95 on Wednesday. Advaxis has a 1-year low of $1.75 and a 1-year high of $9.55.
Several research firms have commented on ADXS. Cantor Fitzgerald set a $19.00 price target on shares of Advaxis and gave the company a “buy” rating in a report on Friday, December 22nd. ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Finally, HC Wainwright set a $23.00 price target on shares of Advaxis and gave the company a “buy” rating in a report on Wednesday, December 27th.
ILLEGAL ACTIVITY WARNING: “Advaxis (ADXS) Issues Quarterly Earnings Results” was originally posted by BBNS and is owned by of BBNS. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://baseballnewssource.com/2018/03/14/advaxis-adxs-issues-quarterly-earnings-results/2029006.html.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.